JAK
Os inibidores de JAK (Janus quinase) são compostos que têm como alvo a via de sinalização JAK-STAT, que está envolvida no crescimento celular, na resposta imunológica e na angiogênese. Ao inibir JAK, esses compostos podem reduzir a sinalização que leva à formação de novos vasos sanguíneos em tumores, inibindo assim o crescimento tumoral. Os inibidores de JAK são importantes no tratamento de cânceres e doenças inflamatórias. Na CymitQuimica, oferecemos uma ampla gama de inibidores de JAK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 245 produtos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SCor e Forma:SolidPeso molecular:566.07PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OCor e Forma:SolidPeso molecular:342.44SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Cor e Forma:SolidPeso molecular:474.52JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Fórmula:C20H18FN5O3SPureza:99.53%Cor e Forma:SolidPeso molecular:427.45JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Fórmula:C20H18ClN7OPureza:98%Cor e Forma:SolidPeso molecular:407.86JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Fórmula:C19H26N8SPureza:98%Cor e Forma:SolidPeso molecular:398.53JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Fórmula:C26H32FN9O2Pureza:98%Cor e Forma:SolidPeso molecular:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Fórmula:C25H32N8O2Pureza:99.64% - 99.87%Cor e Forma:SolidPeso molecular:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Cor e Forma:SolidPeso molecular:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Cor e Forma:SolidPeso molecular:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Cor e Forma:SolidPeso molecular:292.25JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Fórmula:C25H28N8OPureza:97.89%Cor e Forma:SolidPeso molecular:456.54Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Fórmula:C22H26N8Pureza:99.82%Cor e Forma:SolidPeso molecular:402.50STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Cor e Forma:SolidPeso molecular:318.76JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Fórmula:C22H23FN4O3SPureza:98.4%Cor e Forma:SolidPeso molecular:442.51JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Fórmula:C21H21N5O2Pureza:99.59%Cor e Forma:SolidPeso molecular:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Cor e Forma:SoildPeso molecular:591.55JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Cor e Forma:SolidPeso molecular:379.37Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Cor e Forma:SolidPeso molecular:527.66
